Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3458
Name breast adenocarcinoma
Definition A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer breast carcinoma breast adenocarcinoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant Acalisib breast adenocarcinoma sensitive detail...
ERBB2 positive Trastuzumab deruxtecan breast adenocarcinoma sensitive detail...
Unknown unknown Disarib breast adenocarcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00461773 Phase II Letrozole Bevacizumab Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer Unknown status
NCT00796978 Phase II Trastuzumab Trastuzumab in Treating Older Women With Early-Stage Breast Cancer Completed
NCT00826085 Phase Ib/II ThermoDox Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall Completed
NCT01007695 Phase I Valproic acid Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot Terminated
NCT01111825 Phase Ib/II Neratinib + Temsirolimus Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer Completed
NCT01124695 Phase II Tamoxifen Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status
NCT01283789 Phase II Everolimus + Lapatinib Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer Unknown status
NCT01572038 Phase III Pertuzumab + Trastuzumab Nab-paclitaxel Docetaxel Paclitaxel A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE) Completed
NCT01697293 Phase Ib/II Paclitaxel + Triciribine Cyclophosphamide + Doxorubicin Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Terminated
NCT01724606 Phase I Sorafenib Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) Active, not recruiting
NCT01824836 Phase 0 Anastrozole A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Active, not recruiting
NCT01862081 Phase I Docetaxel + Taselisib Paclitaxel + Taselisib A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer Completed
NCT01897441 Phase I Paclitaxel Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer Active, not recruiting
NCT01928589 Phase Ib/II Radiotherapy Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer Recruiting
NCT01959490 Phase II Bevacizumab + Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Docetaxel + Trastuzumab Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer Completed
NCT01973309 Phase I Paclitaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer Completed
NCT02053636 Phase II Lucitanib A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer Completed
NCT02338349 Phase I Elacestrant A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer Completed
NCT02423902 Phase Ib/II Ad-RTS-IL-12 plus AL A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer Unknown status
NCT02450175 Phase I Letrozole Everolimus Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls Unknown status
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Recruiting
NCT02632071 Phase I Nab-paclitaxel + Ricolinostat Phase I of ACY-1215 + Nab-paclitaxel in Breast Cancer Active, not recruiting
NCT02833233 Phase I Ipilimumab + Nivolumab A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer Active, not recruiting
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Active, not recruiting
NCT02964507 Phase II Fulvestrant Fulvestrant + Molibresib Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer Active, not recruiting
NCT03094052 Phase II Neratinib Loperamide Crofelemer Neratinib + Trastuzumab Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Neratinib, With or Without Trastuzumab Recruiting
NCT03199885 Phase III Paclitaxel + Pertuzumab + Trastuzumab Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer Recruiting
NCT03284957 Phase Ib/II SAR439859 Palbociclib + SAR439859 Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer Recruiting
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Suspended
NCT03616587 Phase I AZD9833 AZD9833 + Palbociclib Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer Recruiting
NCT03767335 Phase I CH5132799 + Fulvestrant + Trastuzumab CH5132799 + Trastuzumab MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer (B-PRECISE-01) Recruiting
NCT03778931 Phase III Letrozole Exemestane Elacestrant Fulvestrant Anastrozole Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) Recruiting
NCT03893955 Phase I ABBV-368 + ABBV-927 ABBV-181 + ABBV-368 + ABBV-927 Docetaxel A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT04024800 Phase II AE37 + Pembrolizumab Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14) Recruiting
NCT04176757 Phase I ZN-c5 A Study of ZN-c5 in Participants With Breast Cancer Recruiting
NCT04197687 Phase II Ado-trastuzumab emtansine + Sargramostim + TPIV100 Ado-trastuzumab emtansine + Sargramostim Pertuzumab + Trastuzumab Ado-trastuzumab emtansine TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery Recruiting
NCT04261218 Phase I Paclitaxel + Tomivosertib Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer Recruiting